Literature DB >> 14974087

Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.

Jens Plaschke1, Stefan Krüger, Wolfgang Dietmaier, Johannes Gebert, Christian Sutter, Elisabeth Mangold, Constanze Pagenstecher, Elke Holinski-Feder, Karsten Schulmann, Gabriela Möslein, Josef Rüschoff, Christoph Engel, Gareth Evans, Hans K Schackert.   

Abstract

Germline mutations in mismatch repair (MMR) genes, predominantly in MLH1 and MSH2, are responsible for hereditary nonpolyposis colorectal cancer (HNPCC), a cancer-susceptibility syndrome with high penetrance. In addition, MSH6 mutations have been reported to account for about 10% of all germline mismatch repair (MMR) gene mutations in HNPCC patients, and have been associated with a later age of onset of the disease compared to MLH1 and MSH2 mutations. Here, we report eight novel germline mutations in MSH6. The patients were selected by having developed tumors with loss of MSH6 protein expression. All tumors showed high-level microsatellite instability (MSI-H). Seven mutations resulted in premature stop codons, comprised of two nonsense mutations (c.426G>A [p.W142X], c.2105C>A [p.S702X]), two insertions (c.2611_2614dupATTA [p.I872fsX10], c.3324dupT [p.I1109fsX3]) and three deletions (c.1190_1191delAT [p.Y397fsX3], c.1632_1635delAAAA [p.E544fsX26], c.3513_3514delTA [p.1171fsX5]). In addition, an amino acid substitution of an arginine residue (c.2314C>T [p.R772W]) conserved throughout a wide variety of mutS homologs has been found in a patient not fulfilling the Bethesda criteria for HNPCC. Our results emphasize the suitability of IHC as a pre-selection tool for MSH6 mutation analysis and the high frequency of germline mutation detection in patients with MSH6-deficient tumors. In addition, our findings point towards a broad variability regarding penetrance associated with MSH6 germline mutations. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14974087     DOI: 10.1002/humu.9217

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

Review 1.  History, genetics, and strategies for cancer prevention in Lynch syndrome.

Authors:  Fay Kastrinos; Elena M Stoffel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

2.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

Review 3.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Recently identified colon cancer predispositions: MYH and MSH6 mutations.

Authors:  Fay Kastrinos; Sapna Syngal
Journal:  Semin Oncol       Date:  2007-10       Impact factor: 4.929

5.  Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes.

Authors:  Frank Grünhage; Matthias Jungck; Christoph Lamberti; Christine Berg; Ursula Becker; Hildegard Schulte-Witte; Dominik Plassmann; Nils Rahner; Stefan Aretz; Nicolaus Friedrichs; Reinhard Buettner; Tilman Sauerbruch; Frank Lammert
Journal:  Int J Colorectal Dis       Date:  2007-10-25       Impact factor: 2.571

6.  Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation.

Authors:  Kory W Jasperson; Kathleen R Blazer; Katrina Lowstuter; Jeffrey N Weitzel
Journal:  Fam Cancer       Date:  2008-01-06       Impact factor: 2.375

7.  Colon cancer associated genes exhibit signatures of positive selection at functionally significant positions.

Authors:  Claire C Morgan; Kabita Shakya; Andrew Webb; Thomas A Walsh; Mark Lynch; Christine E Loscher; Heather J Ruskin; Mary J O'Connell
Journal:  BMC Evol Biol       Date:  2012-07-12       Impact factor: 3.260

8.  CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein.

Authors:  Hiroko Terui; Kiwamu Akagi; Hiroshi Kawame; Kei Yura
Journal:  J Biomed Sci       Date:  2013-04-28       Impact factor: 8.410

9.  MSH6 syndrome.

Authors:  Janina Suchy; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

10.  Improved multiplex ligation-dependent probe amplification analysis identifies a deleterious PMS2 allele generated by recombination with crossover between PMS2 and PMS2CL.

Authors:  Annekatrin Wernstedt; Emanuele Valtorta; Franco Armelao; Roberto Togni; Salvatore Girlando; Michael Baudis; Karl Heinimann; Ludwine Messiaen; Noemie Staehli; Johannes Zschocke; Giancarlo Marra; Katharina Wimmer
Journal:  Genes Chromosomes Cancer       Date:  2012-05-14       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.